Document is current
Any future updates will be listed below
-
Authors
Zorina, Olessia https://orcid.org/0009-0001-5809-1369
Beiki, Omid https://orcid.org/0000-0002-3632-2365
Holt, Matthew https://orcid.org/0009-0003-0685-1543
Buisker, Jocelyn
Ferber, Philippe
Fermont, Jilles M. https://orcid.org/0000-0001-5042-5785
Kelly, Richard J. https://orcid.org/0000-0002-3318-9482
-
Funding
Funding for this research was provided by:
Novartis
- License Information
-
More Information
Article History
Received: 16 December 2025
Accepted: 9 March 2026
First Online: 29 May 2026
Declarations
:
: Not applicable.
: Not applicable.
: OZ, JB, PF and JF are full-time employees and shareholders of Novartis Pharma AG. OB is an employee of Cognizant Technology Solutions, under contract to provide literature search-related services to Novartis Pharma AG. MH receives research funding from Sobi and has received support with congress travel from Alexion. RK reports consultancy, research funding, speaker fees, and/or advisory board attendance for Alexion, Amgen, Florio, Novartis Pharma AG, Omeros, Otsuka, Sobi, and Roche.
